Search 2
"meta analysis" OR "systematic literature review" AND ("healthy young adults" OR army OR "armed forces" OR "special forces" OR military OR "elite military" OR operations OR deployed) AND ("dietary supplements" OR "ergogenic aids" OR nutraceuticals OR nootropics OR pharmaceuticals) OR ("performance enhancement" OR "cognitive enhancement" OR cognition OR attention OR memory OR "nutritional armour" OR "nutritional armor") AND ("adverse effects" OR "health outcomes" OR "health concerns" OR safety OR toxicity OR WADA)
Search 3 "meta analysis" OR "systematic literature review" AND ("healthy young adults" OR army OR "armed forces" OR "special forces" OR military OR "elite military" OR operations OR deployed) AND ("dietary supplements" OR "ergogenic aids" OR nutraceuticals OR nootropics OR pharmaceuticals) OR ("performance enhancement" OR "cognitive enhancement" OR cognition OR attention OR memory OR "nutritional armour" OR "nutritional armor") AND ("adverse effects" OR "health outcomes" OR "health concerns" OR safety OR toxicity OR WADA) OR Omega-3 OR Omega-6 OR probiotics OR prebiotics OR "gut-brain axis" OR caffeine OR WADA OR modafinil OR flavonoids OR vitamins OR "gingko biloba" OR bacopa OR curcumin OR ginseng OR protein OR tyrosine)
Search 4 "meta analysis" OR "systematic literature review" AND ("healthy young adults" OR army OR "armed forces" OR "special forces" OR military OR "elite military" OR operations OR deployed) AND micronutrients Vigilance: linear improvement with dose (targets detected p = .046 ;RT: p = .042); VRT: improved (p = .049); Match: NS; Acquisition: improved time to complete (p = .019); Fatigue: reduced at 1 h (p = .02); 8 h (p = .04) Magill et al. Stroop (RT): p = .014, r = 0.26 (DHA faster than placebo); names-to-faces recall: DHA-and EPArich matched fewer items (p = .047, r = 0.21 and p = .013, r = 0.26, respectively); other: NS; Mental fatigue: p = .009, r = 0.27 (EPA-rich lower than placebo) Jackson et al. No moderator Working memory (Nback task: "undemanding" -1back, "demanding" -2back) Load x group (false alarms): p = .02, η 2 p = 0.23, (correct rejections): p = .01, η 2 p = NA, (accuracy): p = .003, η 2 p = 0.35 -2 back task (tyrosine): (false alarms): p = .03, (correct rejections) p= .02, (accuracy) p= .02
Colzato et al. Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
5,6
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
6,7
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
TableS1
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
6,7,8
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
7,8
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
6,41
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. Table S5 Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
8,9
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). TableS6
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
10-27,Table2,Table3
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. NA Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). Table S6 Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).
NA

DISCUSSION
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
27-29
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
2-31
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.
31-33,TableS2,TableS3
FUNDING Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. For more information, visit: www.prisma-statement.org. 
